| 肠促胰岛素类似物和DPP-Ⅳ抑制剂在2型糖尿病治疗中的作用 |
| |
| 引用本文： | 王璐,邸阜生. 肠促胰岛素类似物和DPP-Ⅳ抑制剂在2型糖尿病治疗中的作用[J]. 医学综述, 2007, 13(1): 25-27 |
| |
| 作者姓名： | 王璐 邸阜生 |
| |
| 作者单位： | 天津市第三中心医院代谢科,天津,300170 |
| |
| 摘 要： | 肠促胰岛素类似物(incretin mimetics)是一类具有多种抗高血糖作用的新型降糖药物,它模拟胰升糖素样肽(GLP)-1的作用;二肽基肽酶(DPP-Ⅳ)抑制剂抑制GLP-1的降解。这两类药物的作用机制为:增加葡萄糖依赖的胰岛素分泌;抑制不适当的胰高血糖素分泌增多;增强胰岛素敏感性;减缓胃的排空;和抑制食欲。研究显示,肠促胰岛素类似物和DPP-Ⅳ抑制剂还具有促进胰岛β细胞新生的作用,可能会成为未来2型糖尿病(T2DM)治疗领域的新药。目前,几种肠促胰岛素类似物和DPP-Ⅳ抑制剂正在进行T2DM治疗的末期临床试验。
|
| 关 键 词： | 糖尿病,非胰岛素依赖型 肠促胰岛素类似物 胰升糖素样肽-1 二肽基肽酶-Ⅳ |
| 文章编号： | 1006-2084（2007）01-0025-03 |
| 收稿时间： | 2006-04-26 |
| 修稿时间： | 2006-04-262006-11-14 |
Effect of Incretin Mimetics and DPP- Ⅳ Inhibitors for the Treatment of type 2 Diabetes |
| |
| WANG Lu,DI Fu-sheng. Effect of Incretin Mimetics and DPP- Ⅳ Inhibitors for the Treatment of type 2 Diabetes[J]. Medical Recapitulate, 2007, 13(1): 25-27 |
| |
| Authors: | WANG Lu DI Fu-sheng |
| |
| Affiliation: | Department of Metabolic Disease, The Third Central Hospital in Tianjin , Tianjin 300170, China |
| |
| Abstract: | Incretin mimetics are a new class of pharmacological agents with multiple antihyperglycemic actions,which has mimic actions of incretin hormones such as glucagon-like peptide GLP-1,while,Dipeptidyl peptidase(DPP-Ⅳ) inhibitors suppress the degradation of GLP-1.The mechanism of these two agents includes the enhancement of glucose-dependent insulin secretion,suppression of inappropriately elevated glucagon secretion,enhancement of insulin sensitivity,slowing of gastric emptying and inhibition of appetite.Study demonstrates that incretin mimetics and DPP-Ⅳ inhibitors can promote neogenesis of β-cell and will be a new drug for treatment of T2DM in future.At present,several incretin mimetics and DPP-Ⅳ inhibitors are undergoing late-stage clinical trials for the treatment of type 2 diabetes. |
| |
| Keywords: | Diabetes mellitus,Non-Insulin dependent Incretin mimetics Glucagon-like peptide-1 Dipeptidyl peptidase-Ⅳ |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
